Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TTPA | P49638 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586469 | 0.83 | PTGS2 (0.37) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL4588442 | 0.74 | MAPT (0.35) | MEN1KMT2AALOX15SMN1; SMN2PTGS2 | |
| SCHEMBL11792981 | 0.73 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL1773954 | 0.73 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL437092 | 0.73 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL28277555 | 0.73 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL13396522 | 0.73 | MEN1 (0.51) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL439675 | 0.73 | ALDH1A1 (0.46) | PTGS2 | |
| SCHEMBL13396359 | 0.72 | CA2 (0.43) | MEN1KMT2ACYP2C9ALOX15CYP2C19 | |
| SCHEMBL23943674 | 0.71 | THRB (0.58) | MEN1KMT2AHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | MEN1 4002/4885KMT2A 3995/4885CYP2C9 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.